Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.48 |
| ▸ | ESR1 | P03372 | 2/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9774496 | 0.93 | LMNA (0.87) | LMNAHSD17B10ALDH1A1SMN1; SMN2ESR1 | |
| SCHEMBL10827606 | 0.91 | LMNA (0.83) | LMNAHSD17B10ALDH1A1SMN1; SMN2ESR1 | |
| SCHEMBL50454 | 0.89 | LMNA (0.80) | LMNAHSD17B10ALDH1A1SMN1; SMN2HDAC3 | |
| Hydrochloric Acid SCHEMBL3647676 | 0.87 | LMNA (0.77) | LMNAHSD17B10ALDH1A1SMN1; SMN2HDAC3 | |
| SCHEMBL12135182 | 0.86 | LMNA (0.76) | LMNAHSD17B10ALDH1A1SMN1; SMN2HDAC3 | |
| SCHEMBL8489562 | 0.85 | LMNA (0.73) | LMNAHSD17B10ALDH1A1SMN1; SMN2HDAC3 | |
| SCHEMBL5114421 | 0.82 | LMNA (0.69) | LMNAHSD17B10ALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL11351006 | 0.82 | LMNA (0.68) | LMNAHSD17B10ALDH1A1SMN1; SMN2HDAC3 | |
| SCHEMBL8618054 | 0.81 | LMNA (0.67) | LMNAHSD17B10ALDH1A1SMN1; SMN2HDAC3 | |
| SCHEMBL10050635 | 0.80 | LMNA (0.66) | LMNAHSD17B10ALDH1A1SMN1; SMN2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240165056-A1 | USE OF TAMOXIFEN AND RELATED COMPOUNDS TO REDUCE BREAST IMPLANT CAPSULE FORMATION AND CAPSULAR CONTRACTURE | OHIO STATE INNOVATION FOUNDATION (US) | 2024-05-23 | — | — | US | disclosed |
| EP-4304575-A1 | USE OF TAMOXIFEN AND RELATED COMPOUNDS TO REDUCE BREAST IMPLANT CAPSULE FORMATION AND CAPSULAR CONTRACTURE | Ohio State Innovation Foundation (US) | 2024-01-17 | — | — | EP | disclosed |
| US-11040019-B2 | Selective estrogen-receptor modulators (SERMs) confer protection against photoreceptor degeneration | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-06-22 | — | — | US | disclosed |
| EP-3484463-B1 | SELECTIVE ESTROGEN-RECEPTOR MODULATORS (SERMS) CONFER PROTECTION AGAINST PHOTORECEPTOR DEGENERATION | THE US SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES OFFICE OF TECHNOLOGY TRANSFER (US) | 2020-02-12 | — | — | EP | disclosed |
| US-20190209497-A1 | SELECTIVE ESTROGEN-RECEPTOR MODULATORS (SERMS) CONFER PROTECTION AGAINST PHOTORECEPTOR DEGENERATION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICE (US) | 2019-07-11 | — | — | US | disclosed |
| EP-1952809-B1 | Formulations for the reduction of breast density with 4-Hydroxy Tamoxifen | BESINS HEALTHCARE LU SARL (LU) | 2017-08-02 | — | — | EP | disclosed |
| EP-2050443-B1 | REDUCTION OF BREAST DENSITY WITH 4-HYDROXY TAMOXIFEN | BESINS HEALTHCARE LU SARL (LU) | 2017-05-24 | — | — | EP | disclosed |
| EP-1608353-B1 | PREVENTION AND TREATMENT OF BREAST CANCER WITH 4-HYDROXY TAMOXIFEN | BESINS HEALTHCARE LU SARL (LU) | 2014-04-30 | — | — | EP | disclosed |
| US-8475814-B2 | Prevention and treatment of breast cancer with 4-hydroxy tamoxifen | BESINS HEALTHCARE LUXEMBOURG SARL (LU) | 2013-07-02 | — | — | US | disclosed |
| US-8063249-B1 | Substituted triphenyl butenes | OLEMA PHARMACEUTICALS, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| EP-0151326-A1 | Antiestrogen drug for percutaneous administration | Mauvais-Jarvis, Pierre (FR) | 1985-08-14 | — | — | EP | disclosed |
| WO-1985003228-A1 | ANTI-OESTROGEN DRUG FOR PERCUTANEOUS ADMINISTRATION | MAUVAIS JARVIS PIERRE | 1985-08-01 | — | — | WO | disclosed |
| EP-0054168-B1 | 1,1,2-TRIPHENYL-BUT-1-ENE DERIVATIVES, PROCESS FOR THEIR MANUFACTURE AND THEIR USE AS PHARMACEUTICAL AGENTS | Klinge Pharma GmbH (DE) | 1984-07-11 | — | — | EP | disclosed |
| EP-0019377-B1 | 1-HYDROCARBYLOXYPHENYL-1,2-DIPHENYLALKENE DERIVATIVES, THEIR MANUFACTURE AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1982-08-04 | — | — | EP | disclosed |
| EP-0054168-A1 | 1,1,2-Triphenyl-but-1-ene derivatives, process for their manufacture and their use as pharmaceutical agents | Klinge Pharma GmbH (DE) | 1982-06-23 | — | — | EP | disclosed |
| US-4307111-A | ANTIESTROGENS | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1981-12-22 | — | — | US | disclosed |
| EP-0002097-B1 | TRIPHENYLALKENE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1981-08-05 | — | — | EP | disclosed |
| EP-0019377-A1 | 1-Hydrocarbyloxyphenyl-1,2-diphenylalkene derivatives, their manufacture and a pharmaceutical composition containing them | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1980-11-26 | — | — | EP | disclosed |
| US-4206234-A | Triphenylbut-1-ene derivatives and pharmaceutical compositions and uses thereof | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1980-06-03 | — | — | US | disclosed |
| EP-0002097-A1 | Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1979-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240165056-A1 | USE OF TAMOXIFEN AND RELATED COMPOUNDS TO REDUCE BREAST IMPLANT CAPSULE FORMATION AND CAPSULAR CONTRACTURE | CYP19A1, SHBG, PGR | LMNA 4360/4885HSD17B10 354/4885ALDH1A1 1694/4885 |
| US-20190209497-A1 | SELECTIVE ESTROGEN-RECEPTOR MODULATORS (SERMS) CONFER PROTECTION AGAINST PHOTORECEPTOR DEGENERATION | NR2E3, ESR2, ESR1 | LMNA 2544/4885HSD17B10 1732/4885ALDH1A1 232/4885 |
| US-11040019-B2 | Selective estrogen-receptor modulators (SERMs) confer protection against photoreceptor degeneration | NR2E3, ESR2, ESR1 | LMNA 2544/4885HSD17B10 1732/4885ALDH1A1 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.